Diaceutics PLC Directorate Change (4359J)

TIDMDXRX

RNS Number : 4359J

Diaceutics PLC

22 December 2020

Diaceutics PLC

("Diaceutics" or the "Company" or the "Group")

Directorate change

Diaceutics PLC (AIM: DXRX), announces the resignation of Julie Goonewardene as Non-Executive Chair. Julie will step down on 31 December 2020. Having been with Diaceutics for almost 10 years Julie has, with the support of the Board, decided to step down.

Julie Goonewardene commented : "It has been my pleasure and privilege to work with the Diaceutics team for the better part of a decade. I have enjoyed the journey of helping guide the Company from a small Irish boutique consultancy to a global publicly traded data enabled platform firm. My goal has always been to see the Company reach the important milestone of launching its transformative platform, DXRX, and together we have achieved this objective. DXRX has great potential and I look forward to seeing how it transforms the diagnostics industry."

Peter Keeling, Chief Executive Officer of Diaceutics said: "Julie has been a trusted partner and friend through all of the growth stages of the Company and a key contributor to our most successful strategies right up to the successful IPO in March 2019. On behalf of the Board, we would like to thank Julie for all her hard work and the support she has given us during her time with Diaceutics. She has been a valued member of the Group, and we are sad to see her go."

Enquiries:

 
 Diaceutics PLC                                                                   www.diaceutics.com 
 Peter Keeling, Chief Executive                                                      via Walbrook PR 
  Officer 
 Philip White, Chief Financial 
  Officer 
 
 Cenkos Securities plc (Nominated adviser 
  and broker)                                                                   [phone] 
 Callum Davidson / Giles 
  Balleny 
 Michael Johnson (Sales) 
 
 Walbrook PR                                   Tel: [phone] or [e-mail] 
 Anna Dunphy                                                                Mob: [phone] 
 Paul McManus                                                               Mob: [phone] 
 
 

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - a proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries. www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAKKDBNOBDDOBB

(END) Dow Jones Newswires

December 22, 2020 02:00 ET (07:00 GMT)